CAS: 57576-44-0; Aclacinomycin A

上下游产品

(+)-aklavinone 3',3'-didesmethyl-aclarubicin (+)-aklavinone 3,5,5-trimethyl-2-oxomorpholine 5,6-dihydro-3,5,5-trimethyl-1,4-oxazin-2-one

阿克拉菌酮置于soybean Meal,Dipotassium Hydrogenphosphate,葡萄糖,Ke303 Of S. Galilaeus Ma144-M1,Magnesium Sulfate,Copper(II) Sulfate,Iron(II) Sulfate,Zinc(II) Sulfate,Sodium Chloride,Manganese(Ll) Chloride,Starch,Yeast Extract体系中,用 水 作为反应溶剂,化学反应 96.0H,反应生成 阿克拉霉素,Aclacinomycin X
参考文献:New Betaclamycin And Aclarubicin Analogs Obtained By Prolonged Microbial Conversion With An Aclarubicin-Negative Mutant.
标题:New Betaclamycin And Aclarubicin Analogs Obtained By Prolonged Microbial Conversion With An Aclarubicin-Negative Mutant.
摘要:使用一种阿克拉霉素阴性链霉菌(streptomyces Galilaeus)突变体对β-罗多霉素酮和阿克拉维酮进行微生物转化,获得了新的蒽环类抗生素cg21-C和cg1-C,它们在每个加合的糖苷的c-7处具有红苷-2-脱氧岩藻糖基-罗多霉素三糖残基.它们仅在长时间转化培养时产生.由于通常的转化产物含有红苷-2-脱氧岩藻糖基-罗多霉素残基,在进一步培养过程中首先积累然后减少,很明显它们是通过末端红苷的修饰而产生的.本文描述了分离,纯化和结构测定,并讨论了体外对培养的l1210细胞的细胞毒性和形成机制.
DOI:10.7164/antibiotics.49.669

专利信息

专利号:US-2012177593-A1
优先权日:2009-07-20
标 题 :Synthesis of dendrimer conjugates
发明人：BAKER JR JAMES R; ZHANG YUEHUA; THOMAS THOMMEY P; DESAI ANKUR MAHESH
权利人:BAKER JR JAMES R; ZHANG YUEHUA; THOMAS THOMMEY P; DESAI ANKUR MAHESH; UNIV MICHIGAN
摘要:The present invention relates to novel methods of synthesis of therapeutic and diagnostic dendrimers. In particular, the present invention is directed to novel dendrimer conjugates, novel methods of synthesizing the same, compositions comprising the conjugates, as well as systems and methods utilizing the conjugates (e.g., in diagnostic and/or therapeutic settings (e.g., for the delivery of therapeutics, imaging, and/or targeting agents (e.g., in disease (e.g., cancer, inflammatory disease) diagnosis and/or therapy, pain therapy, etc.)). Accordingly, dendrimer conjugates of the present invention may further comprise at least two different components for targeting, imaging, sensing, and/or providing a therapeutic or diagnostic material and/or monitoring response to therapy. Furthermore, the novel synthesis methods of certain embodiments of the present invention provide significant advantages with regard to total reaction time and simplicity.

专利号:US-12391691-B2
优先权日:2018-11-16
标题:Synthesis of key intermediate of KRAS G12C inhibitor compound
发明人：PARSONS ANDREW THOMAS; COCHRAN BRIAN MCNEIL; POWAZINIK IV WILLIAM; CAPORINI MARC ANTHONY
权利人:AMGEN INC
摘要:The present invention relates to an improved, efficient, scalable process to prepare intermediate compounds, such as compound 5M, having the structure n nuseful for the synthesis of compounds that target KRAS G12C mutations, such as

专利号:US-2010137421-A1
优先权日:2006-11-08
标题 :Small molecule therapeutics, synthesis of analogues and derivatives and methods of use
发明人：THEODORAKIS EMMANUEL; BATOVA AYSE
权利人:THEODORAKIS EMMANUEL; BATOVA AYSE
摘要:Provided herein are compounds that are inducers of apoptosis activators of caspases and pharmaceutically acceptable derivatives thereof. Also provided are methods of synthesis of the compounds and methods for treatment of diseases in which there is uncontrolled cell growth and spread of abnormal cells, such as cancers, by administering the compounds.

专利号:US-2025206736-A1
优先权日:2019-11-14
标题 :Synthesis of kras g12c inhibitor compound
发明人：CORBETT MICHAEL THOMAS; CAILLE SEBASTIEN
权利人:AMGEN INC
摘要:The present disclosure relates to an improved, efficient, scalable process to prepare intermediate compounds, such as 2-isopropyl-4-methylpyridin-3-amine, useful for the synthesis of compounds, such as Compound 9, for the treatment of KRAS G12C mutated cancers.

专利号:EP-0113566-A1
优先权日:1982-12-20
标题:New intermediate compounds for synthesis of aklavinones and their preparation
发明人：KISHI YOSHITO
权利人:MEIJI SEIKA KAISHA
摘要:A new compound of the formulan wherein R, is a hydrogen atom, a hydroxyl group or an alkoxyl group of 1-4 carbon atoms and R 2 is an alkyl group of 1-4 carbon atoms is now provided. This new compound is useful as intermediate for synthesis of aklavinones which may be coupled with sugars, for example, daunosamine to give anthracycline antibiotics. The new compound of this invention is produced by several reaction steps started from a 3-halo-5-substituted or unsubstituted naphthoquinone and a furan diene compound. This process involves new regiospecific Diels-Alder condensation and new asymmetric crossed aldol condensation.

专利号:WO-2017100796-A1
优先权日:2015-12-11
标 题 :Modulation of globoseries glycosphingolipid synthesis and cancer biomarkers
发明人：WONG CHI-HUEY; HSU TSUI-LING; WU CHUNG-YI; CHEUNG SARAH K C; CHUANG PO-KAI
权利人:SINACA ACAD; WONG CHI-HUEY; HSU TSUI-LING
摘要:The present disclosure relates to methods and compositions which can modulate the globoseries glycosphingolipid synthesis. Particularly, the present disclosure is directed to glycoenzyme inhibitor compound and compositions and methods of use thereof that can modulate the synthesis of globoseries glycosphingolipid SSEA-3/SSEA-4/GloboH in the biosynthetic pathway; particularly, the glycoenzyme inhibitors target the alpha-4GalT; beta- 4GalNAcT-I; or beta-3GalT-V enzymes in the globoseries synthetic pathway. Additionally, the present disclosure is also directed to vaccines, antibodies, and/or immunogenic conjugate compositions targeting the SSEA-3/SSEA-4/GLOBO H associated epitopes (natural and modified) which elicit antibodies and/or binding fragment production useful for modulating the globoseries glycosphingolipid synthesis. Moreover, the present disclosure is also directed to the method of using the compositions described herein for the treatment or detection of hyperproliferative diseases and/or conditions. Furthermore, the instant disclosure also relates to cancer stem cell biomarkers for disgnostic and therapeutic uses.